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Jasvinder A Singh1,2,3* and David G Lewallen3Abstract
Background: Few, if any data are available are available regarding the time-trends in characteristics of patients who
have undergone primary THA. Our objective was to examine the time-trends in key demographic and clinical
characteristics of patients undergoing primary total hip arthroplasty (THA).
Methods: We used the data from the Mayo Clinic Total Joint Registry from 1993–2005 to examine the time-trends
in demographics (age, body mass index (BMI)), medical (Deyo-Charlson index) and psychological comorbidity
(anxiety, depression) and underlying diagnosis of patients undergoing primary THA. Chi-square test and analysis
for variance were used. Multivariable-adjusted logistic regression (age, sex, comorbidity-adjusted) compared
1993–95 to other study periods. Odds ratio (OR) and 95% confidence interval (CI) are presented.
Results: The primary THA cohort consisted of 6,168 patients with 52% women. In unadjusted analyses, compared
to 1993–95, significantly more patients (by >2-times for most) in 2002–05 had: BMI ≥ 40, 2.3% vs. 6.3%; depression, 4.1%
vs. 9.8%; and anxiety, 3.4% vs. 5.7%; and significantly fewer had an underlying diagnosis of rheumatoid/inflammatory
arthritis, 3.7% vs. 1.5% (p ≤ 0.01 for all). In multivariable-adjusted models, compared to 1993–95, significantly more patients
in 2003–05 had (all p-values ≤ 0.01): BMI ≥ 40, OR, 2.79 (95% CI: 1.85, 4.22); Deyo-Charlson Index ≥ 3, 1.32 (1.07, 1.63);
depression, 2.25 (1.66, 3.05); and anxiety, 1.71 (1.19, 2.15). Respectively, fewer patients had a diagnosis of RA/inflammatory
arthritis: 0.28 (0.17, 0.46; p < 0.01). Over the 13-year study period, Deyo-Charlson index increased by 22% (0.9 to 1.1) and
the mean age decreased by 0.7 years (65.0 to 64.3) (p < 0.01 for both).
Conclusions: Obesity, medical and psychological comorbidity increased and the underlying diagnosis of RA/inflammatory
arthritis decreased rapidly in primary THA patients over 13-years. Our cohort characteristics are similar to previously
described characteristics of national U.S. cohort, suggesting that these trends may be national rather than local trends.
This is important information for policy makers to take into account for resource allocation. Studies of THA outcomes and
utilization should take these rapidly changing patient characteristics into account.
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Total hip arthroplasty (THA) has been called the operation
of the century [1]. Primary THA is the second most
common joint replacement surgery performed in the
U.S. [2], associated with a significant improvement in
patient outcomes [3]. The utilization of primary THA
is rapidly increasing and 478,000 primary THA procedures
were performed in the U.S. in 2009 [4,5]. Recent studies
have described the time-trends in THA utilization
[6-10], outcomes [6,8-11] and select patient characteristics
(age, obesity) [6,9,10]. On the other hand, time-trends in
important characteristics of patients undergoing THA,
including body mass index (BMI), medical/ psychological
comorbidity etc. associated with THA outcomes, have not
been examined. Most studies were done in non-U.S.
settings [8,11], except three key studies using data
from the Medicare [6], the National Inpatient sample
(NIS) [9] and the National Hospital Discharge Survey
(NHDS) [10]. Several knowledge gaps exist in this
area, as summarized in the following section.
In Medicare recipients 65 years and older, the number
of comorbidities increased from 1.0 to 2.0 and obesity
rates increased from 2.2% to 7.6% from 1991 to 2008 [6].
Representative studies of the U.S. NIS from 1998 to
2008 and U.S. NHDS data 1990 to 2004, that included
all age groups, showed that among patients undergoing
THA, age decreased by 2.1 years [9], Deyo comorbidity
index increased from 0.48 to 0.65 [9] and obesity increased
from 2.2% to 3.8% [10]. Data from these Medicare, NIS and
NHDS studies are limited in several important aspects: (1)
obesity, linked to THA outcomes [12-15], was captured
with a diagnostic code, which is associated with significant
under-coding compared to when using the weight and
height data [16], as evident in low obesity rates <5% in
these studies vs. U.S. obesity rates of 37% in 2009, proving
that the use of ICD-9 code for obesity leads to high
misclassification rate [17]; and (2) anxiety, depression
and underlying diagnosis, important predictors of
THA outcomes [14,18-22], were not assessed. Data
from Medicare study are additionally limited in that
they are not representative, since at least 1/3rd of all
THAs are performed in those younger than 65 years
[23,24], the fastest growing age group for the receipt of
THA over time [25]. A recent study in TKA cohort found
that rates of extreme obesity, Deyo-Charlson index
score > =3, depression and anxiety increased 2–3 fold
from 1993–2005 [26]. To our knowledge, there is lack
of such data for time-trends in BMI, anxiety, depression
and underlying diagnoses in patients undergoing THA
in the U.S.
One of the most remarkable changes in the epidemiology
of primary THA in the last two decades is the expanding
indication of THA to both younger and older patients.
Studies have not examined whether the time-trends inimportant clinical characteristics (BMI, underlying diagno-
sis and medical and psychiatric comorbidity) vary by age,
the most rapidly changing characteristic of patients
undergoing primary THA. Knowing how the patient
complexity has changed over time is critically important,
since these patient characteristics can have a significant
impact on THA outcomes. Our objectives were to: (1)
examine the time trends in BMI, underlying diagnosis and
medical and psychiatric comorbidity in patients undergoing
primary THA; and (2) assess whether these time-trends are
different in various patient age groups.
Methods
We report the methods and results as recommended in
the Strengthening of Reporting in Observational studies
in Epidemiology (STROBE) statement [27].
Study cohort selection
The Mayo Clinic Total Joint Registry, a large institutional
registry that has prospectively collected preoperative and
postoperative follow-up data on all THA patients at the
Mayo Clinic, Rochester, served as the data source for this
study [28]. Preoperative data, the focus of this study, are
collected at the in-clinic visit by the orthopedic surgeons
using a standardized data collection form. Since 1993,
trained, dedicated Total Joint Registry staff has captured
and entered these data into electronic database and
ensured the completeness of data. The Mayo Clinic’s
Institutional Review Board approved the research study.
All investigations were conducted in conformity with
ethical principles of research.
Study outcomes
The study period was divided into roughly equal four
intervals (1993–95, 1996–98, 1999–2001 and 2002–05).
The study outcomes of interest were patient’s demographic
and clinical characteristics and medical and psychological
comorbidity. Patient characteristics and clinical variables
were categorized as follows. BMI was categorized as <25,
overweight, 25–29.9, obese and very obese (obesity class I
and II), 30–39.9, or extremely obese (obesity class III), ≥40
as previously [14,29,30], as per WHO classification [31].
Age was categorized as <50, 50- < 65, 65- < 80, ≥80, to allow
comparison to other studies using Medicare data that only
include patients 65 years and older. The operative diagnosis
was categorized as osteoarthritis, rheumatoid arthritis
(RA)/inflammatory arthritis and other.
Medical comorbidity was assessed with the Deyo-
Charlson index [32], a validated measure of comorbidity.
It is a summative weighted score based on the presence
of 17 comorbidities (including cardiac, pulmonary,
renal, hepatic disease, diabetes, cancer, hemiplegia etc.)
[33,34], captured based on the presence of International
Classification of Diseases, ninth revision, common
Table 1 Preoperative patient characteristics of the
primary THA cohort







50- < 65 1626 (26%)
65- <80 2947 (48%)
≥80 620 (10%)


















Age, mean (SD) 64.2 (13.8)
Deyo-Charlson Index, mean (SD) 1.0 (1.9)
BMI, mean (SD) 28.9 (5.8)
Missing data: BMI, n = 25; ASA score, n = 26; Underlying diagnosis, n = 1.
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index was categorized as none, one, two and three or more,
similar to previous studies [35], and comorbidities were also
assessed individually. Depression and anxiety were assessed
based on the presence of ICD-9-CM diagnostic codes.
Statistical analyses
We calculated summary statistics as proportion or
mean (standard deviation). We used chi-square tests
to compare the proportions of patients with each category
of patient characteristic (BMI, underlying diagnosis,
Deyo-Charlson index, depression and anxiety) over
time, and also also comparisons of categorical variables in
1993–95 vs. 2005–08. We used the analysis of variance to
compare means (age, BMI, Deyo-Charlson index) in
various time periods.
We also examined the time trends in the proportion
of patients with extreme obesity (BMI ≥40; obesity class
III) and high comorbidity (Deyo-Charlson index ≥3) using
logistic regression. We examined the time trends in
BMI ≥40, RA/inflammatory arthritis as underlying diagno-
sis, Deyo-Charlson index of ≥3, depression and anxiety,
within each age group, using multivariable-adjusted logis-
tic regression analyses. Time-period was considered in
four category nominal variable (1993–1995, reference
category), and the BMI <40, other diagnoses, Deyo-Charlson
index of ≤2 and absence of depression or anxiety serving
as the reference category for each respective outcome.
The overall p-value for the variable was considered as an
indicator of whether there was a period effect; visual
inspection of the odds ratios was interpreted for time-
trend. We performed statistical analyses using Statistical
Package for Social Sciences (SPSS, version 21, Chicago, IL).
A p-value <0.05 was considered significant.
Results
The primary THA cohort consisted or 6,168 patients,
52% were women, 10% were 80 years or older, 5% had
BMI of 40 or more, 38% had ASA grade III-IV, the
underlying diagnosis was OA in 87% and 64% had
cemented/hybrid implant fixation (Table 1).
Time trends in socio-demographic and clinical
characteristics and comorbidity
The mean age decreased by 0.7 years and mean BMI
increased by 1.6 kg/m2 over the 13-year period of study,
both statistically significant. The prevalence of BMI ≥30
(obesity class I-III) and ≥40 (obesity class III) increased
from 33.2% to 37.1% and 2.3% to 6.3% during the study
period, respectively. The proportion of younger patients
(≤50 years) increased from 13.7% to 16% and the
prevalence of RA/inflammatory arthritis as the underlying
diagnosis decreased from 3.7% in 1993–95 to 1.3% in
2002–05 (Table 2). The proportion of primary THApatients with Deyo-Charlson score of 3 or more increased
from 12.2% to 15.1%. The prevalence of psychological
comorbidity increased over the study period: depression
increased >2-fold from 4.5% to 9.8% and anxiety from
3.4% to 5.7% (Table 2).
Compared to 1993–95, significantly more patients
(by >2-times for most) in 2002–05 had: BMI ≥ 40,
2.3% vs. 6.3%; depression, 4.1% vs. 9.8%; and anxiety,
3.4% vs. 5.7%; and significantly fewer had an under-
lying diagnosis of rheumatoid/inflammatory arthritis,
3.7% vs. 1.5% (p ≤ 0.01 for all comparisons using chi-square
tests).
The prevalence for several Deyo-Charlson comorbidities
increased significantly over the study period and the
Table 2 Time trends in demographics and clinical characteristics of patients undergoing primary THA, in %, unless
specified otherwise
1993-1995 1996-1998 1999-2001 2002-2005 P-value
Age category 0.002
<50 13.7 17.1 16.2 16.0
50- < 65 24.7 25.9 26.6 27.5
65- <80 51.8 48.8 47.2 44.9
≥80 9.8 8.2 10.0 11.6
Mean age (SD) 65.0 (13.2) 63.5 (14.0) 63.9 (14.0) 64.3 (13.9) 0.03
Female gender 51.8 50.0 52.0 51.9 0.67
BMI <0.001
<25 28.1 26.0 24.0 21.5
25–29.9 38.8 40.0 37.9 37.2
30–34.9 23.5 24.1 23.6 25.8
35–39.9 7.3 6.6 9.1 9.3
≥40 2.3 3.3 5.3 6.3
Mean BMI (SD) 28.0 (5.2) 28.3 (5.2) 29.1 (6.0) 29.6 (6.2) <0.001
Operative Diagnosis <0.001
Osteoarthritis 81.8 81.0 88.2 92.2
RA/inflammatory arthritis 3.7 3.7 2.4 1.3
Other 14.5 15.3 9.4 6.5
Deyo-Charlson Index <0.001
0 61.9 63.2 59.2 56.7
1 17.3 17.2 15.4 16.2
2 8.7 9.3 11.0 11.9
3 or more 12.2 10.2 14.4 15.1
Depression 4.5 4.8 7.2 9.8 <0.001
Anxiety 3.4 3.5 4.9 5.7 0.003
SD, standard deviation; RA, rheumatoid arthritis, BMI, body mass index.
Significant p-values are in bold. We used analysis of variance for continuous variables and, chi-squared test for categorical variables.
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22% (Table 3).
Time trends in key patient characteristics within each age
group
We noted a significant increase in prevalence of BMI ≥40
(>2-fold increase each) in two age groups, 50- < 65 and
65- < 80 (Table 4). Similarly, a significant decline in the
underlying diagnosis of RA/inflammatory arthritis was
noted in the two age groups, those <50 years from 17.9%
to 4.2% (77% reduction) and in those 65- < 80 years from
3.5% to 1.2% (66% reduction). The proportion of patients
with Deyo-Charlson index of 3 or more increased in
65- < 80 years group, from 16.1% to 19.9% (23% increase;
Table 4). The prevalence of depression increased signifi-
cantly across all four age groups, most impressive in
patients younger than 50 years, from 2.9% to 8.3% (almost
3-fold). The prevalence of anxiety increased in all age
groups, but was not statistically significant, except fora trend in 80 and older age group, from 3.4% to 5.7%
(p = 0.06; Table 4).
Unadjusted and adjusted odds in key patient
characteristics over time
In the unadjusted analyses, compared to 1993–95, the
odds of BMI ≥40 in the next three time periods were
1.46, 2.43 and 2.90 (Table 5). These odds attenuated
minimally after adjusting for age-, sex- and comorbidity in
the multivariable-adjusted models (Table 5). Compared to
1993–95, the unadjusted odds of RA/inflammatory
arthritis as the underlying diagnosis were 1.00, 0.59
and 0.31 in the three next time periods (Table 5). The
respective unadjusted odds for medical and psychological
comorbidity were as follows: (1) for Deyo-Charlson index
of 3 or more, 0.82, 1.21 and 1.28; (2) depression, 1.07, 1.64
and 2.30; and (3) anxiety, 1.04, 1.48 and 1.74, respectively
(Table 5). The higher odds for Deyo-Charlson, depres-
sion and anxiety also were minimally attenuated with
Table 3 Time trends in prevalence of medical comorbidity (in %) from 1993 to 2005 in patients undergoing primary THA
1993-1995 1996-1998 1999-2001 2002-2005 P-value
Deyo-Charlson comorbidities
Myocardial Infarction 4.0 4.2 4.1 4.7 0.76
Congestive Heart Failure 2.5 2.8 3.5 4.1 0.05
Peripheral Vascular Disease 4.7 3.8 4.2 5.6 0.07
Cerebrovascular disease 5.5 5.2 6.3 7.9 0.006
Dementia 0 0 0.3 0.4 0.02
COPD 9.7 8.8 10.2 9.7 0.66
Peptic ulcer disease 5.5 6.3 6.2 6.3 0.81
Mild liver disease 1.4 0.6 1.1 1.2 0.20
Diabetes 4.8 5.0 5.9 8.0 <0.001
Diabetes with end organ damage 0.9 0.7 1.8 2.0 0.005
Hemiplegia 0.3 0.2 0.2 0.5 0.48
Moderate/severe renal disease 2.6 3.2 5.4 5.9 <0.001
Moderate/severe liver disease 0.5 0.3 0.2 0.3 0.58
Metastatic solid tumor 3.3 2.3 3.6 2.7 0.12
AIDS 0 0.1 0 0 0.32
Rheumatologic disease 6.1 5.2 5.4 5.2 0.67
Other cancer 11.2 10.9 13.5 13.9 0.02
Mean Deyo-Charlson score (SD) 0.9 (1.8) 0.9 (1.7) 1.1 (2.0) 1.1 (2.0) <0.001
COPD, Chronic Obstructive Pulmonary Disease; AIDS, Acquired Immune Deficiency Disease; SD, standard deviation.
Significant p-values are in bold, calculated with chi-squared test.
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multivariable-adjusted models (Table 5).
Discussion
In this study in patients undergoing primary THA, we
found increasing rates of obesity, medical and psychological
comorbidity and a decreasing rate of RA/inflammatory
arthritis as the underlying diagnosis over time. To our
knowledge, this is the first study to comprehensively
examine time-trends in depression, anxiety, medical
comorbidities and underlying diagnosis, overall and in
different age groups of patients undergoing primary
THA. The younger age group is the fastest growing group
for the receipt of THA over time among all age groups
[23,25]. Several study findings deserve further discussion.
A key finding from our study was that the prevalence
of obesity, including extreme obesity (BMI ≥40), differed
significantly by time and seemed to increase over time. By
using the height and weight data prospectively captured in
the joint registry, we were able to get accurate estimates of
obesity and overcame a key limitation of under-diagnosis
of obesity based on the use of ICD-9-CM diagnostic code
[16] in all the previous studies [6,10]. Among the patients
undergoing primary THA, obesity increased from 33.2%
in 1992–95 to 37.1% for in 2002–05. In the U.S. Medicare
population, the prevalence of obesity was reported to
increase from 2.2% in 1991 to 7.6% in 2008 [6] andin the NIS from 2.2% in 1990 to 5.0% in 2004 [10]. Thus,
our study is the first to examine the change in BMI over
time in a U.S. cohort undergoing THA. The prevalence of
obesity of 37% in our 2002–2005 cohort was higher than
the 24.5% reported in 2004 for the general U.S. population
[17]. Comparing the prevalence of obesity of 5% in the
NIS study using the ICD-9 code to the 37% using height
and weight data in our study, highlights the extent of
under-coding of obesity using ICD-9-CM codes in admin-
istrative databases (by 7-fold relative and 32% absolute dif-
ference) and the resulting misclassification in earlier
studies. Our cohort's demographic and clinical character-
istics are similar to those reported from the U.S. NIS, indi-
cating that our sample is representative. This should be
comforting to clinicians who might be worried that our
institution does not have a representative population,
since the Mayo Clinic provides THA to local resi-
dents and is also a referral center. To our knowledge,
no systematic changes occurred in referral patterns
from primary care physicians to orthopedic surgery or
policy for reimbursement for primary THA (except
slight uniform reduction in compensation across the
health care system) in the U.S. during the study period
that would explain the time-trends in these characteristics.
Another contribution from our study to the literature was
our ability to provide overall and age-specific time-trends
in BMI and to examine time-trends in extreme obesity.
Table 4 Time-trends in patient characteristics (in %) by patient age category from 1993 to 2005 in patients
undergoing primary THA
1993-1995 1996-1998 1999-2001 2002-2005 P-value
BMI ≥40
Age, <50 1.1 7.3 7.2 5.8 0.30
Age, 50- < 65 3.5 5.3 7.1 9.3 0.007
Age, 65- <80 2.4 1.3 4.6 5.7 <0.001
Age ≥80 0 0 1.3 2.2 0.17
Diagnosis of RA/inflammatory arthritis
Age, <50 17.9 10.5 6.2 4.2 <0.001
Age, 50- < 65 2.6 3.3 1.9 1.0 0.11
Age, 65- <80 3.5 4.2 2.3 1.2 0.002
Age ≥80 0 0 1.4 0 0.11
Deyo-Charlson Index ≥3
Age, <50 5.7 1.7 4.8 4.8 0.16
Age, 50- < 65 4.1 6.7 7.8 8.2 0.13
Age, 65- <80 16.1 12.7 19.8 19.9 <0.001
Age ≥80 20.8 24.1 21.9 27.2 0.51
Depression
Age, <50 2.9 3.0 6.0 8.3 0.02
Age, 50- < 65 5.4 4.8 8.7 9.4 0.02
Age, 65- <80 4.7 5.2 6.8 9.1 0.002
Age ≥80 4.0 6.3 7.1 15.8 0.001
Anxiety
Age, <50 1.7 0.9 2.4 2.9 0.41
Age, 50- < 65 2.2 2.2 4.9 3.9 0.12
Age, 65- <80 4.1 5.1 4.8 6.6 0.14
Age ≥80 3.4 3.5 4.9 5.7 0.06
Significant p-values are in bold, calculated with chi-squared test.
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of the rates of extreme obesity in 50- < 65 and 65- < 80
age groups and of depression in all 4 age groups. To
our knowledge this is the first study to examine these
important patient characteristics in various age groups,
over time. Examination of these characteristics (extreme
obesity, depression etc.) by age groups provides a detailed
knowledge of their variation over time by age in primary
THA patients. This knowledge can also allow policy
makers to direct their efforts towards the group that is
most at risk due to rapidly increasing prevalence of these
clinical features that are associated with poor prognosis
and worse outcomes after primary THA [12,15,18,19,36].
We also found that the prevalence of RA/inflammatory
arthritis reduced by 65-75% in <50 and 65- < 80 age groups
over the study period. This finding adds to the growing
evidence that fewer patients with RA/inflammatory arthritis
are requiring THA, compared to 1–2 decades ago [5,37,38].
This may at least partially be due to the availability and
more frequent use of effective disease-modifying treatmentsfor RA, including methotrexate and/or biologics [39,40], as
recommended in the RA treatment guidelines [41,42].
The time-trends in the prevalence of extreme obesity,
depression and anxiety were mostly independent of age,
gender and medical comorbidity, as demonstrated in the
multivariable-adjusted models. Anxiety and depression
are well-recognized predictors of poorer pain and function
outcomes after arthroplasty [14,43-45]. This is an important
finding, since there were significant time trends of
decreasing patient age and increasing medical comorbidity
over the same time-period. We noted minimal attenuation
of odds ratios comparing unadjusted to multivariable-
adjusted models, implying that increasing obesity, depres-
sion and anxiety in primary THA patients is not the result
of increasing medical comorbidity or decreasing age.
In our study, we found rapidly increasing prevalence
of moderate to severe renal disease, cerebrovascular
disease and dementia over time. To our knowledge, this
has not been reported previously in primary THA patients.
This finding indicates that surgeons and patients need to
Table 5 Unadjusted and adjusted odds of extreme obesity (BMI of 40 or higher), an underlying operative diagnosis of
RA/inflammatory arthritis, Deyo-Charlson index of 3 or higher, depression or anxiety over time
1993-1995 1996-1998 1999-2001 2002-2005
BMI ≥40
Unadjusted Ref 1.46 (0.91, 2.35) 2.43 (1.58, 3.73)* 2.90 (1.92, 4.37)*
Age- and sex-adjusted Ref 1.41 (0.85, 2.26) 2.36 (1.53, 3.63)* 2.84 (1.88, 4.29)*
Comorbidity-adjusted Ref 1.47 (0.92, 2.37) 2.40 (1.56, 3.69* 2.87 (1.90, 4.33)*
Age-, sex- and comorbidity adjusted Ref 1.42 (0.88, 2.28) 2.30 (1.50, 3.55)* 2.79 (1.85, 4.22)*
Diagnosis of RA/inflammatory arthritisa
Unadjusted Ref 1.00 (0.67, 1.50) 0.59 (0.38, 0.91)¶ 0.31 (0.19, 0.51)*
Age- and sex-adjusted Ref 0.97 (0.65, 1.46) 0.55 (0.35, 0.85)† 0.29 (0.18, 0.48)*
Comorbidity-adjusted Ref 1.00 (0.67, 1.51) 0.58 (0.38, 0.90)¶ 0.31 (0.19, 0.50)*
Age-, sex- and comorbidity adjusted Ref 0.99 (0.66, 1.48) 0.53 (0.34, 0.83)† 0.28 (0.17, 0.46)*
Deyo-Charlson Index ≥3b
Unadjusted Ref 0.82 (0.64, 1.04) 1.21 (0.97, 1.51) 1.28 (1.04, 1.58)¶
Age- and sex-adjusted Ref 0.86 (0.67, 1.10) 1.26 (1.01, 1.58)¶ 1.32 (1.07, 1.63)†
Depression
Unadjusted Ref 1.07 (0.74, 1.53) 1.64 (1.18, 2.27)† 2.30 (1.70, 3.11)*
Age- and sex-adjusted Ref 1.09 (0.76, 1.56) 1.65 (1.19, 2.29)† 2.31 (1.71, 3.13)*
Comorbidity-adjusted Ref 1.09 (0.76, 1.56) 1.59 (1.15, 2.21)† 2.24 (1.66, 3.04)*
Age-, sex- and comorbidity adjusted Ref 1.11 (0.77, 1.59) 1.60 (1.15, 2.22)† 2.25 (1.66, 3.05)*
Anxiety
Unadjusted Ref 1.04 (0.69, 1.59) 1.48 (1.01, 2.17)¶ 1.74 (1.22, 2.49)†
Age- and sex-adjusted Ref 1.09 (0.72, 1.66) 1.51 (1.03, 2.21)¶ 1.75 (1.22, 2.51)†
Comorbidity-adjusted Ref 1.07 (0.70, 1.62) 1.44 (0.98, 2.11) 1.70 (1.18, 2.43)†
Age-, sex- and comorbidity adjusted Ref 1.10 (0.73, 1.68) 1.47 (1.00, 2.15) 1.71 (1.19, 2.15)†
Ref, reference category, has an odds ratio of 1.0.
aOsteoarthritis is the reference category for diagnosis.
bSince the variable under study was Deyo-Charlson index, comorbidity-adjusted models were not run.
¶P < 0.05; †P ≤ 0.01; *P ≤ 0.001.
Significant odds ratios are in bold.
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time, which may be associated with an increase in
peri-operative complications. This needs further study.
Our study confirms several previous findings including
a reduction in mean age and increase in Deyo-Charlson
index for patients undergoing primary THA. Findings
from the study of the U.S. NIS showed that Deyo-Charl-
son index increased 0.42 to 0.55 (30% increase) from
1998–2008 in patients undergoing THA [9], similar to
the 36% increase noted in our study. The magnitude of
increases is lower compared to a 100% increase of co-
morbidity from 1 to 2 in Medicare sample from 1991
to 2008 [6]. This is not surprising due to the inclusion of
all-comers in our and the NIS study vs. only patients
65 years and older (with higher comorbidity) in the
Medicare sample. Our study also confirms a doubling
of the prevalence of diabetes in patients undergoing
primary THA over last 10–15 years, as reported in
analyses of Medicare (7.1% in 1991–92 to 15.5% in2007–08) [6] and the NIS data (6.8% in 1990–94 to
11% in 2000–04) [10].
Our study showed that the change in primary THA
patient characteristics with increasing obesity and medical
and psychological comorbidity is evident. These time-
trends need to be accounted in research studies of THA
outcomes and when health care plans and policy makers
are making the reimbursement and coverage decisions.
Data on several important patient characteristics are
limited or absent in Medicare and NIS datasets that
can be examined more comprehensively using data
from total joint registries, similar to ours.
Our study has several limitations that should be taken
into account while interpreting study findings. Our co-
hort study is subject to residual confounding due to
study design, despite the adjustment for several important
covariates in our multivariable-adjusted analyses. We used
ICD-9 diagnostic codes to define anxiety and depression,
and therefore these are likely under-reported. In addition,
Singh and Lewallen BMC Musculoskeletal Disorders 2014, 15:441 Page 8 of 9
http://www.biomedcentral.com/1471-2474/15/441the increasing incidence of anxiety and depression over
time might indicate either a better capture/reporting of
these or a true increase in its incidence in this patient
population. We are unable to distinguish between these
two possibilities.
Study strengths include the use of height/weight data for
BMI, a representative sample from a well-established U.S.
total joint registry, availability of electronically captured data
for more than a decade and robustness of our findings
across several sensitivity models (age-adjusted vs. age- and
sex-adjusted vs. age, sex- and comorbidity-adjusted
models). The similarity of our cohort to other published
studies of THA [8,12,13,46] as well as the NIS sample
[9,47], supports the generalizability of these findings.
Conclusion
In conclusion, we observed an increasing prevalence
of obesity, medical and psychological comorbidity and
decreasing prevalence of RA/inflammatory arthritis over a
13-year study period in patients undergoing primary THA.
The time-trends differed by the age category. These time-
trends in patient characteristics should be accounted for
when comparing results over time and performing studies
that include several years of data. Our study findings should
be resource for public policy makers and those comparing
resource use across interventions and procedures and
making reimbursement decisions. These data represent
the changing complexity of primary THA patients in the
U.S., which can potentially impact outcomes.
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